Boehringer Ingelheim’s NexGard PLUS Receives the US FDA’s Approval to Protect Dogs from Internal and External Parasites
Shots:
- The US FDA has approved afoxolaner, moxidectin & pyrantel chewable tablets (NexGard PLUS), a new one-and-done monthly combination product for canine protection from fleas, ticks, heartworm disease, roundworms & hookworms
- Multiple clinical studies showed that NexGard PLUS was safe & effective, ≥99.8% effective 24hrs. in killing adult fleas fast after weekly infestations for a full month after treatment, 100% effective in preventing heartworm disease in dogs, safe for puppies as young as 8wks. & in P-gp-deficient (MDR1-mutant) avermectin-sensitive dogs
- Boehringer Ingelheim’s beef-flavored afoxolaner, moxidectin & pyrantel chewable tablets are expected to be available for veterinary clinics on July 2023
Ref: PR Newswire | Image: Boehringer Ingelheim
Related News:- Boehringer Ingelheim Reports the Commercial Availability of Cyltezo, an Interchangeable Biosimilar to Humira
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
